Mitochondria-Targeting Biquaternary Ammonium Compounds: Pancreatic Anticancer Activity and Synergistic Interaction...

Area of Science:

• Oncology
• Medicinal Chemistry
• Biochemistry

Background:

• Pancreatic cancer presents significant treatment challenges due to chemotherapy resistance, metastasis, and late diagnosis.
• Existing therapies are often compromised by these factors, necessitating novel therapeutic strategies.
• The anticancer potential of bis-quaternary ammonium-based compounds (BQACs) is largely unexplored.

Purpose of the Study:

• To investigate the anticancer activity and structure-activity relationship of amphiphilic bicationic compounds (BQACs).
• To evaluate the selectivity of BQACs against pancreatic cancer cells.
• To explore combination therapies of BQACs with existing chemotherapeutic agents, specifically metformin.

Main Methods:

• Synthesis and characterization of novel BQACs.
• In vitro antiproliferative assays on pancreatic cancer cell lines.
• Mitochondrial accumulation and membrane potential studies.
• Combination therapy studies with metformin and assessment of cellular uptake.

Main Results:

• BQACs demonstrated potent antiproliferative effects on pancreatic cancer cells.
• Mitochondrial accumulation and depolarization were identified as key mechanisms of action.
• Combination of BQACs with metformin enhanced metformin cellular uptake.
• Synergistic effects were observed, allowing for a significantly lower effective dose of metformin.

Conclusions:

• BQACs represent a promising class of compounds with selective anticancer activity against pancreatic cancer.
• Mitochondrial targeting is a viable strategy for BQAC-mediated cancer cell death.
• The combination of BQACs and metformin offers a synergistic approach to enhance pancreatic cancer treatment efficacy.